CPC A61K 31/506 (2013.01) [A61K 9/0053 (2013.01); A61P 9/12 (2018.01)] | 8 Claims |
1. A method of inhibiting the formation of 5-HT in a human patient comprising:
administering to the patient a therapeutically effective amount of a compound of (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof,
wherein the compound is in substantially crystalline form, and
wherein the therapeutically effective amount is about 1 mg/kg/day to about 50 mg/kg/day.
|